Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial

Central grade and luminal-A-like subtype were significant predictors of outcome if genomic grade as dichotomous factor (GG1/EQ vs. GG3) was included into the multivariate analysis in breast cancer patients treated by EC-Doc or FEC within the EC-Doc trial. Only continuous GGI but not IHC4 was strong prognostic factor beyond all other factorsin HR+/HER2- breast cancer even if central grade was available.

from Cancer via ola Kala on Inoreader http://ift.tt/1oytDsD
via IFTTT